Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full ...

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

Historical patterns indicate that abrupt fluctuations in the market can impact any firm, regardless of its seeming dominance.

PFE stock decreased 30.0% from a peak of $40.71 on January 23, 2020, to $28.49 on March 23, 2020, compared to a ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

SHANGHAI, Feb 24 (Reuters) - Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ...

(Reuters) -Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder approval, securing a path into the fast-growing obesity ...

Management provided a 2026 adjusted total revenue target of $230 million to $270 million, including $35 million to $45 million of Nuvaxovid product sales under existing orders, $40 million to $50 ...

Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa ...

Is Pfizer's 6% yield a rare opportunity hiding in plain sight, or are investors overlooking a major risk that could reshape ...